ATE449073T1 - Verfahren zur herstellung von n1-(2-pyridyl)-1,2- propandiaminsulfamidsäure und ihre verwendung zur herstellung von biologisch aktiven piperazinen - Google Patents

Verfahren zur herstellung von n1-(2-pyridyl)-1,2- propandiaminsulfamidsäure und ihre verwendung zur herstellung von biologisch aktiven piperazinen

Info

Publication number
ATE449073T1
ATE449073T1 AT07007755T AT07007755T ATE449073T1 AT E449073 T1 ATE449073 T1 AT E449073T1 AT 07007755 T AT07007755 T AT 07007755T AT 07007755 T AT07007755 T AT 07007755T AT E449073 T1 ATE449073 T1 AT E449073T1
Authority
AT
Austria
Prior art keywords
producing
propanediaminesulfamid
pyridyl
acid
biologically active
Prior art date
Application number
AT07007755T
Other languages
English (en)
Inventor
Anita W Chan
Gregg B Feigelson
Joseph Zeldis
Ivo Jirkovsky
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE449073T1 publication Critical patent/ATE449073T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/76Nitrogen atoms to which a second hetero atom is attached
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT07007755T 2002-03-12 2003-03-10 Verfahren zur herstellung von n1-(2-pyridyl)-1,2- propandiaminsulfamidsäure und ihre verwendung zur herstellung von biologisch aktiven piperazinen ATE449073T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36345702P 2002-03-12 2002-03-12

Publications (1)

Publication Number Publication Date
ATE449073T1 true ATE449073T1 (de) 2009-12-15

Family

ID=28041771

Family Applications (2)

Application Number Title Priority Date Filing Date
AT07007755T ATE449073T1 (de) 2002-03-12 2003-03-10 Verfahren zur herstellung von n1-(2-pyridyl)-1,2- propandiaminsulfamidsäure und ihre verwendung zur herstellung von biologisch aktiven piperazinen
AT03716415T ATE360002T1 (de) 2002-03-12 2003-03-10 Verfahren zur herstellung von n1-(2'-pyridyl)-1,2-propandiaminsulfamidsäure und ihre verwendung zur herstellung von biologisch aktiven piperazinen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT03716415T ATE360002T1 (de) 2002-03-12 2003-03-10 Verfahren zur herstellung von n1-(2'-pyridyl)-1,2-propandiaminsulfamidsäure und ihre verwendung zur herstellung von biologisch aktiven piperazinen

Country Status (27)

Country Link
US (1) US6784294B2 (de)
EP (2) EP1801103B1 (de)
JP (1) JP4397693B2 (de)
KR (1) KR20040091720A (de)
CN (1) CN100341854C (de)
AR (1) AR038932A1 (de)
AT (2) ATE449073T1 (de)
AU (1) AU2003220122A1 (de)
BR (1) BR0308315A (de)
CA (1) CA2477886A1 (de)
CY (1) CY1106677T1 (de)
DE (2) DE60330199D1 (de)
DK (1) DK1483243T3 (de)
EC (1) ECSP045291A (de)
ES (2) ES2283762T3 (de)
HK (1) HK1068618A1 (de)
IL (1) IL163829A0 (de)
MX (1) MXPA04008731A (de)
NO (1) NO20044049L (de)
NZ (1) NZ535170A (de)
PT (1) PT1483243E (de)
RU (1) RU2314294C2 (de)
SI (1) SI1483243T1 (de)
TW (1) TWI288642B (de)
UA (1) UA80272C2 (de)
WO (1) WO2003078396A1 (de)
ZA (1) ZA200408213B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060223824A1 (en) * 2000-11-28 2006-10-05 Wyeth Serotonergic agents
US7504395B2 (en) * 2001-07-20 2009-03-17 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder
ATE449073T1 (de) 2002-03-12 2009-12-15 Wyeth Corp Verfahren zur herstellung von n1-(2-pyridyl)-1,2- propandiaminsulfamidsäure und ihre verwendung zur herstellung von biologisch aktiven piperazinen
US7361773B2 (en) * 2002-03-12 2008-04-22 Wyeth Preparation of N1-(2'-pyridyl)-1,2-propanediamine sulfamic acid and its use in the synthesis of biologically active piperazines
IL163828A0 (en) * 2002-03-12 2005-12-18 Wyeth Corp Process for making chiral 1,4-disubstituted piperazines
US20050215561A1 (en) * 2004-03-19 2005-09-29 Krishnendu Ghosh Pharmaceutical dosage forms and compositions
US20070099931A1 (en) * 2004-03-19 2007-05-03 Wyeth Pharmaceutical dosage forms and compositions
PA8626301A1 (es) * 2004-03-19 2006-12-07 Wyeth Wyeth Proceso para preparar derivados de n-aril-piperazina
JP2008531694A (ja) * 2005-03-01 2008-08-14 ワイス 結晶性および非晶性4−シアノ−n−{(2r)−2−[4−(2,3−ジヒドロ−ベンゾ[1,4]ジオキシン−5−イル)−ピペラジン−1−イル]−プロピル}−n−ピリジン−2−イル−ベンズアミド塩酸塩
WO2011111831A1 (ja) 2010-03-12 2011-09-15 日本曹達株式会社 ピリジン環含有化合物、及びハロゲン化ピコリン誘導体及びテトラゾリルオキシム誘導体の製造方法
EP2602248A1 (de) 2011-12-05 2013-06-12 University Of Leicester Neue Pyrrol Verbindungen
GB201310126D0 (en) * 2013-06-06 2013-07-24 Univ Leicester Novel pyrrole derivatives

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE81975T1 (de) * 1984-12-21 1992-11-15 Duphar Int Res Arzneimittel mit psychotroper wirkung.
JPH01125357A (ja) 1987-11-06 1989-05-17 Dainippon Pharmaceut Co Ltd トリペプチドの誘導体
MX9201991A (es) * 1991-05-02 1992-11-01 Jonh Wyeth & Brother Limited Derivados de piperazina y procedimiento para su preparacion.
WO1994024115A1 (en) 1993-04-16 1994-10-27 Santen Pharmaceutical Co., Ltd. Novel piperazine derivative
DK0763024T3 (da) * 1994-06-03 2002-12-02 Wyeth John & Brother Ltd Fremgangmåde og mellemprodukter til fremstilling af piperazinderivater
GB9411099D0 (en) 1994-06-03 1994-07-27 Wyeth John & Brother Ltd Piperazine derivatives
GB9514901D0 (en) * 1995-07-20 1995-09-20 American Home Prod Piperazine derivatives
JP2000508319A (ja) 1996-04-10 2000-07-04 メルク エンド カンパニー インコーポレーテッド αvβ3拮抗薬
ATE449073T1 (de) 2002-03-12 2009-12-15 Wyeth Corp Verfahren zur herstellung von n1-(2-pyridyl)-1,2- propandiaminsulfamidsäure und ihre verwendung zur herstellung von biologisch aktiven piperazinen
CA2477892C (en) * 2002-03-12 2010-11-23 Gregg Brian Feigelson Process for synthesizing chiral n-aryl piperazines

Also Published As

Publication number Publication date
UA80272C2 (en) 2007-09-10
RU2314294C2 (ru) 2008-01-10
DE60330199D1 (de) 2009-12-31
WO2003078396A8 (en) 2004-01-29
ATE360002T1 (de) 2007-05-15
PT1483243E (pt) 2007-06-27
ES2283762T3 (es) 2007-11-01
JP4397693B2 (ja) 2010-01-13
DK1483243T3 (da) 2007-08-06
US20030204087A1 (en) 2003-10-30
HK1068618A1 (en) 2005-04-29
ZA200408213B (en) 2007-03-28
MXPA04008731A (es) 2004-12-06
ES2334836T3 (es) 2010-03-16
WO2003078396A1 (en) 2003-09-25
JP2005526088A (ja) 2005-09-02
EP1801103B1 (de) 2009-11-18
AU2003220122A1 (en) 2003-09-29
CN100341854C (zh) 2007-10-10
AR038932A1 (es) 2005-02-02
EP1483243B1 (de) 2007-04-18
NZ535170A (en) 2006-03-31
BR0308315A (pt) 2004-12-28
EP1801103A1 (de) 2007-06-27
CA2477886A1 (en) 2003-09-25
SI1483243T1 (sl) 2007-08-31
TW200303751A (en) 2003-09-16
NO20044049L (no) 2004-09-24
DE60313301T2 (de) 2007-12-27
RU2004130314A (ru) 2005-04-10
ECSP045291A (es) 2004-10-26
KR20040091720A (ko) 2004-10-28
EP1483243A1 (de) 2004-12-08
TWI288642B (en) 2007-10-21
CY1106677T1 (el) 2012-05-23
CN1642916A (zh) 2005-07-20
DE60313301D1 (de) 2007-05-31
IL163829A0 (en) 2005-12-18
US6784294B2 (en) 2004-08-31

Similar Documents

Publication Publication Date Title
ATE476412T1 (de) Acyl-4-carboxy-phenyl-harnstoffderivate, verfahren zu deren herstellung und deren verwendung
ATE473227T1 (de) 5,6-dialkyl-7-amino-triazolopyrimidine, verfahren zu ihrer herstellung und ihre verwendung zur bekämpfung von schadpilzen sowie sie enthaltende mittel
DE60328421D1 (de) Verfahren zur herstellung von super-hydrophoben oberflächen, daraus hergestellte oberflächen und deren verwendung
DE60325690D1 (de) Halbleiterbauelement und verfahren zu seiner herstellung
DE60313602D1 (de) N-iPHENYL(PIPERIDIN-2-YL)METHYLöBENZAMIDDERIVATE,VERFAHREN ZU IHRER HERSTELLUNG UND IHRE THERAPEUTISCHE ANWENDUNG
DE60324376D1 (de) Halbleiterbauelement und Verfahren zu dessen Herstellung
DE50310782D1 (de) Piezoaktor und verfahren zu dessen herstellung
ATE449073T1 (de) Verfahren zur herstellung von n1-(2-pyridyl)-1,2- propandiaminsulfamidsäure und ihre verwendung zur herstellung von biologisch aktiven piperazinen
ATE327981T1 (de) Arylisoxazolin-derivative, verfahren zu ihrer herstellung und ihre verwendung als schädlingsbekämpfungsmittel
DE60323994D1 (de) Verfahren zur herstellung von 2-chlor-1,1,1,2,3,3,3-heptafluorpropan, hexafluorpropen und 1,1,1,2,3,3,3-heptafluorpropan
DE60239493D1 (de) Halbleiterbauelement und verfahren zu seiner herstellung
ATE496046T1 (de) Arylvinylazacycloalkan-verbindungen und verfahren zu deren herstellung und verwendung
DE502004005578D1 (de) Hochtackige klebmasse, verfahren zu deren herstellung und deren verwendung
DE60307830D1 (de) Neue multimerische moleküle, verfahren zu deren herstellung, und deren verwendung zur herstellung von arzneimitteln
DE60236790D1 (de) Piezoelektrischer oszillator und verfahren zu seiner herstellung
ATE514431T1 (de) Allergie-vakzine-zusammensetzung, herstellungsverfahren dafür und ihre verwendung bei der behandlung von allergien
DE50206824D1 (de) Befestigungselement und verfahren zu seiner herstellung sowie verwendung
AT502793A5 (de) Grobkeramischer formkörper, verfahren zu dessen herstellung und verwendung
ATE404532T1 (de) Acyl-3-carboxyphenyl-harnstoffderivate, verfahren zu deren herstellung und deren verwendung
ATE439356T1 (de) Verfahren zur herstellung von chiralen n-aryl piperazinen
DE60223714D1 (de) Verfahren zur herstellung von monofilamenten aus polypropylen, monofilamente aus polypropylen sowie deren verwendung
ATE302765T1 (de) 2-arylimino-2,3-dihydrothiazol derivate, verfahren zu ihrer herstellung und ihre therapeutische verwendung
DE60121826D1 (de) Fibrinmaterial und verfahren zu seiner herstellung und verwendung
DE60307458D1 (de) System und verfahren zur herstellung von lasteinheiten
ATE404545T1 (de) Acylaminothiazolderivate, verfahren zu deren herstellung und deren verwendung als inhibitoren der produktion von beta-amyloidpeptid

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties